Kawai et al., 2021 - Google Patents
Melanoma inhibitory activity and melanoma inhibitory activity 2 as novel immunohistochemical markers of oral epithelial dysplasiaKawai et al., 2021
View HTML- Document ID
- 10955133982295502832
- Author
- Kawai R
- Sugita Y
- Suzumura T
- Hattori T
- Yoshida W
- Kubo K
- Maeda H
- Publication year
- Publication venue
- Journal of Clinical Medicine
External Links
Snippet
Oral potentially malignant disorders are associated with the development of oral squamous cell carcinoma (OSCC). Most OSCCs are diagnosed via histopathology as oral epithelial dysplasia (OED), but the histologic diagnostic criteria remain non-uniform. Accordingly, the …
- 102100008436 MIA 0 title abstract description 107
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/01—Social networking
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/10—Office automation, e.g. computer aided management of electronic mail or groupware; Time management, e.g. calendars, reminders, meetings or time accounting
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce, e.g. shopping or e-commerce
- G06Q30/02—Marketing, e.g. market research and analysis, surveying, promotions, advertising, buyer profiling, customer management or rewards; Price estimation or determination
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Inamura | Update on immunohistochemistry for the diagnosis of lung cancer | |
Meyer et al. | 2021 update on diagnostic markers and translocation in salivary gland tumors | |
Ecke et al. | UBC® rapid test—a urinary point-of-care (POC) assay for diagnosis of bladder cancer with a focus on non-muscle invasive high-grade tumors: results of a multicenter-study | |
Barone et al. | Bladder cancer and risk factors: data from a multi-institutional long-term analysis on cardiovascular disease and cancer incidence | |
Broggi et al. | Immunohistochemical expression of ABCB5 as a potential prognostic factor in uveal melanoma | |
Giraldi et al. | Pathologic characteristics of pregnancy-related meningiomas | |
Hsu et al. | The co-expression of programmed death-ligand 1 (PD-L1) in untreated EGFR-mutated metastatic lung adenocarcinoma | |
Van der Fels et al. | EpCAM expression in lymph node metastases of urothelial cell carcinoma of the bladder: a pilot study | |
Müller et al. | Expression of SEC62 oncogene in benign, malignant and borderline melanocytic tumors—unmasking the wolf in sheep’s clothing? | |
Urbano et al. | 18F–Choline PET/CT Identifies High-Grade Prostate Cancer Lesions Expressing Bone Biomarkers | |
Capodiferro et al. | Intra-cystic (in situ) mucoepidermoid carcinoma: a clinico-pathological study of 14 cases | |
Soundararajan et al. | Genotype-to-phenotype associations in the aggressive variant prostate cancer molecular profile (AVPC-m) components | |
Kim et al. | Midkine and NANOG have similar immunohistochemical expression patterns and contribute equally to an adverse prognosis of oral squamous cell carcinoma | |
Kawai et al. | Melanoma inhibitory activity and melanoma inhibitory activity 2 as novel immunohistochemical markers of oral epithelial dysplasia | |
Paladino et al. | Immunomorphological Patterns of Chaperone System Components in Rare Thyroid Tumors with Promise as Biomarkers for Differential Diagnosis and Providing Clues on Molecular Mechanisms of Carcinogenesis | |
Blinova et al. | Relapse-Free Survival and PD-L1 Expression in First High-and Low-Grade Relapsed Luminal, Basal and Double-Negative P53-Mutant Non-Muscular Invasive Bladder Cancer Depending on Previous Chemo-and Immunotherapy | |
Mizoguchi et al. | Granzyme B expression in the tumor microenvironment as a prognostic biomarker for patients with triple-negative breast cancer | |
López-García et al. | Low prevalence of HER2-positive breast carcinomas among screening detected breast cancers | |
Salvatorelli et al. | Immunoexpression of macroh2a in uveal melanoma | |
Viculin et al. | Elevated tumor cell-intrinsic STING expression in advanced laryngeal cancer | |
Miligy et al. | Pathological changes following neoadjuvant endocrine therapy (NAET): a multicentre study of 391 breast cancers | |
Ding et al. | MBD3 as a potential biomarker for colon cancer: implications for epithelial-mesenchymal transition (EMT) pathways | |
Delgado et al. | BUBR1 as a Prognostic Biomarker in Canine Oral Squamous Cell Carcinoma | |
Lee et al. | Biphasic thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with a prominent spindle cell component: a case report | |
Dumitru et al. | Proliferating Lymphatic Endothelial Cells as a Prognostic Marker in Head and Neck Squamous Cell Carcinoma |